ADVA delivers unprecedented precision in timing networks with TrueTime™
29.9.2020 10:00:00 EEST | Business Wire | Press release
ADVA (FSE: ADV) today announced a new and robust way to deliver unprecedented levels of precision in timing networks. Built on ADVA’s TrueTime™ technology, this new end-to-end solution will prove key for 5G, smart grid and other time-sensitive applications. Unlike other delivery mechanisms, TrueTime™ uses PTP-optimized optical transport to provide accurate synchronization from the core of the network all the way to the edge. It does this by combining ePRTC core clocks and ultra-precise boundary clocks to ensure nanosecond timing. Not only does this method provide PRTC levels of accuracy, but it’s also more robust than any competing solution and this is key in the battle to mitigate the risk of GNSS vulnerabilities. What’s more, in greenfield deployments, TrueTime™ enables service providers to reduce the number of PRTC core clocks and GNSS equipment, simplifying network management and reducing costs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200929005114/en/
ADVA’s TrueTime™ solution will prove vital for 5G, smart grid and other time-sensitive applications (Graphic: Business Wire)
“Our TrueTime™ solution addresses some of the most urgent challenges for operators of critical infrastructure. It enables highly accurate synchronization throughout the transport network and offers a future-proof way to tackle the risk of reliance on satellite-based timing. From governments concerned with the growing risk of blocked GNSS signals to mobile network operators rolling out next-generation services, our TrueTime™ technology will prove invaluable,” said Henning Hinderthür, VP, product line management, ADVA. “TrueTime™ combines our PTP-optimized FSP 3000 optical transport with our ultra-precise Oscilloquartz technology, including PTP grandmasters with ePRTC capabilities in the core and boundary clock class D technology in metro locations. This even reduces cost and complexity by eliminating the need for unnecessary equipment, enabling operators to streamline their timing infrastructure.”
ADVA TrueTime™ offers new levels of robust and precise synchronization for even the most challenging applications. It achieves this by using a bidirectional channel to deliver SyncE and PTP traffic. Accuracy is ensured by PRTC/ePRTC core clocks featuring OSA 5430/40 in combination with OSA 3230/3350 cesium atomic clocks. Closely-spaced, out-of-band wavelengths help TrueTime™ tackle asymmetric delay and leave all other channels available for customer traffic. What’s more, every element of the TrueTime™ solution is transparently controlled by ADVA’s Ensemble Controller and Ensemble Sync Director management system, featuring Syncjack™ monitoring technology. As well as being the market’s only complete end-to-end solution combining timing, transport and assurance technology, TrueTime™ offers the benefits of a fully integrated synchronization overlay solution. This empowers operators to protect their investment by harnessing rapid innovation cycles.
“All across the world, governments and businesses are realizing that network timing based on GNSS is vulnerable to failure, disruption and interference. Ensuring backup is now seen as a mandatory step towards secure synchronization. What we’re announcing today leverages two key Oscilloquartz innovations: Our boundary clocks now meet class D performance and use multiple clock domains for link redundancy, and our fully redundant ePRTC solutions utilize our new optical atomic clocks. This means that operators can ensure PRTC quality in greenfield networks without the need to invest in PRTCs at every single site,” commented Nir Laufer, senior director, product line management, Oscilloquartz, ADVA. “From our newly enhanced boundary clocks and unique optical cesium technology to the flexible ADVA FSP 3000 open line system, each element is a pre-integrated part of our TrueTime™ solution. And for ultimate efficiency and ease of use, every piece is under the management umbrella of our comprehensive Ensemble Controller and Ensemble Sync Director.”
Further information on TrueTime™ is available in these slides: https://adva.li/tt-sync-slides.
A supporting solution brief can also be downloaded: https://adva.li/tt-sync-brief.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we're creating new opportunities for tomorrow's networks. For more information, please visit us at www.oscilloquartz.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200929005114/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
